953 reports of this reaction
3.7% of all CANAKINUMAB reports
#4 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #4 most commonly reported adverse reaction for CANAKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 953 FDA adverse event reports linking CANAKINUMAB to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 3.7% of all 25,877 adverse event reports for this drug.
Patients taking CANAKINUMAB who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is moderately reported among CANAKINUMAB users, representing a notable but not dominant share of adverse events.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for CANAKINUMAB:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 953 FDA reports for CANAKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 3.7% of all adverse event reports for CANAKINUMAB, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking CANAKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.